FDA authorizes Omicron-specific boosters
The U.S. Food and Drug Administration on Wednesday authorized updated, Omicron-specific COVID-19 boosters from both Pfizer and Moderna, multiple outlets report.
The new shots are expected post-Labor Day, pending review from the Centers for Disease Control and Prevention later this week, notes The Washington Post. The boosters' bivalent formula targets both the BA.4 and BA.5 Omicron subvariant, as well as the original strain of the virus that circulated back in 2020.
The agency notably cleared the jabs without data from human trials, which it argued could detrimentally slow the process and perhaps render moot any data used in authorization, per The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Pfizer's booster was cleared for use in individuals ages 12 and up, while the Moderna shot was authorized for those 18 and older. Prospective recipients must wait at least two months after finishing their primary series of vaccinations or after receiving their last booster dose to get the new shot.
"As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose," FDA Commissioner Robert Califf said Wednesday.
The Biden administration is preparing to distribute the shots as part of its fall booster campaign, NBC News adds.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Is there a Christmas curse on Downing Street?
Today's Big Question Keir Starmer could follow a long line of prime ministers forced to swap festive cheer for the dreaded Christmas crisis
By The Week UK Published
-
Are pig-organ transplants becoming a reality?
The Explainer US woman has gene-edited pig-kidney transplant, and scientists hope experimental surgery could save thousands of lives
By Abby Wilson Published
-
Blake Lively's 'bombshell' legal action
In the spotlight It Ends With Us actor files 'astonishing' court filing against co-star and director Justin Baldoni
By Chas Newkey-Burden, The Week UK Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published